<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>EXtend and eXjange were prospective, 1-yr, non-interventional, observational, multicentre studies that investigated <z:chebi fb="0" ids="49005">deferasirox</z:chebi>, a once-daily oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi>, in iron-overloaded chelation-naïve and prechelated patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), respectively, treated in the daily-routine setting of office-based physicians </plain></SENT>
<SENT sid="1" pm="."><plain>No inclusion or exclusion criteria or additional monitoring procedures were applied </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> was administered as recommended in the European Summary of Product Characteristics </plain></SENT>
<SENT sid="3" pm="."><plain>Haematological parameters and adverse events (AEs) were collected at two-monthly intervals </plain></SENT>
<SENT sid="4" pm="."><plain>Data from 123 chelation-naïve patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (mean age 70.4 yrs) with median baseline serum ferritin level of 2679 (range 184-16,500) ng/mL, and 44 prechelated patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (mean age 69.6 yrs) with median baseline serum ferritin level of 2442 (range 521-8565) ng/mL, were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>The mean prescribed daily dose of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> at the first visit was 15.7 and 18.7 mg/kg/d, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with <z:chebi fb="0" ids="49005">deferasirox</z:chebi> produced a significant reduction in median serum ferritin levels in chelation-naïve patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from 2679 to 2000 ng/mL (P = 0.0002) and a pronounced decrease in prechelated patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from 2442 to 2077 ng/mL (P = 0.06) </plain></SENT>
<SENT sid="7" pm="."><plain>The most common drug-related AEs were gastrointestinal, <z:hpo ids='HP_0003259'>increased serum creatinine</z:hpo> levels and <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These studies demonstrate that <z:chebi fb="0" ids="49005">deferasirox</z:chebi> used in physicians' medical practices is effective in managing iron burden in transfusion-dependent patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>